Latest Updates
-
Happy Eid 2026: Top 50+ Eid Mubarak Wishes, Messages And Quotes To Share With Friends, Family And Colleagues -
Pav Bhaji Recipe: Master it with One Simple Trick -
Gangaur 2026: Marriage Delays Holding You Back? This Simple Remedy Can Move Wedding Plans Forward -
Social Media Influencer Yuvraj Dua’s Reel About His ‘Modi-Paglu’ Papa Goes Viral, PM Modi Reacts Online -
Matsya Jayanti 2026 Falls On March 21: Rituals, Muhurat, And The Meaning Behind Vishnu’s Avatar -
Soft Idli Sambar Recipe: Your Ultimate Breakfast Delight -
Horoscope for Today March 21, 2026 - Fresh Start & Clear Choices -
Pigmentation Before Peak Summer: Expert Insights On Why Indian Skin Is More Vulnerable -
Mutton Curry Recipe: The Original Method Revealed -
Ranveer Singh Spotted Wearing ₹22 Lakh Rolex Cosmograph Daytona In Dhurandhar 2, Signals Hamza's Power Shift
Actos Reduces Conversion To Type 2 Diabetes
A new study has shown that people in prediabetic state were 81 pct less likely to convert into type 2 diabetes patients when treated with drug pioglitazone, brand name Actos®.
Lead researcher Dr. Ralph A. DeFronzo, professor and chief of diabetes at The University of Texas Health Science Center at San Antonio, said the study also showed that the patients randomized to take pioglitazone also recovered part of their insulin production and their bodies became more sensitive to insulin, therefore using it more efficiently to control plasma glucose or blood sugar,
“Prediabetes, I believe, is really diabetes," said Dr. DeFronzo.
The study involved 602 individuals with impaired glucose tolerance, a prediabetic state, along with 102 healthy controls.
Pioglitazone corrects two core defects in type 2 diabetes, insulin resistance and beta cell failure. Beta cells are the cells in the pancreas that secrete insulin.
“The drug is the best insulin sensitizer we have and it also preserves beta cell function. The clinical response in this study is next to astronomical, not 100 percent but obviously highly significant."
The findings revealed that 10 subjects with impaired glucose tolerance developed diabetes while taking pioglitazone as compared to 45 subjects with impaired glucose tolerance who developed diabetes after receiving a placebo.
It also showed that 42 percent of individuals in the pioglitazone arm of the study returned to normal glucose tolerance at the study"s end versus 28 percent of those in the placebo arm.
Currently, no drug is approved by the U.S. Food and Drug Administration for treatment of prediabetes to prevent progression to diabetes.
A drug to treat impaired glucose tolerance and prevent further decline is therefore of great importance.
The findings were presented on June 9 during the 68th Scientific Sessions of the American Diabetes Association in San Francisco.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications











